CLINICAL_TRIALS
trial_result
· 2016-10-26
Clinical Trial Update: Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size [Phase 3]
Summary
Phase 3 trial testing early mineralocorticoid receptor antagonist therapy to reduce infarct size in ST-elevation myocardial infarction has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University College, London | Conditions: ST-elevation Myocardial Infarction | Phase 3 | Status: COMPLETED